World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
75
Citations
24618
World Ranking
1964
National Ranking
20

Overview

Inge Marie Svane is affiliated with Copenhagen University Hospital in Denmark. Their research primarily lies within the fields of Medicine and Immunology and Microbiology, with a focus on oncology and immunology subfields. Their work encompasses several subfields including Oncology, Immunology, Molecular Biology, Genetics, and Pulmonary and Respiratory Medicine.

Their main research topics include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, cutaneous melanoma detection and management, melanoma and MAPK pathways, immune cell function and interaction, and virus-based gene therapy research.

Frequent collaborators in their research include Marco Donia, Eva Ellebæk, Lars Bastholt, Özcan Met, and Troels Holz Borch.

They have published extensively in various scientific venues. The most frequent publication venues include:

  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Immuno-Oncology Technology

Selected recent papers authored or co-authored by Svane illustrate the scope and impact of their research:

  • Tertiary lymphoid structures improve immunotherapy and survival in melanoma, 2020, Nature
  • Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma, 2022, New England Journal of Medicine
  • Clinical advances and ongoing trials of mRNA vaccines for cancer treatment, 2022, The Lancet Oncology
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1, 2020, Nature Immunology

Best Publications

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

    Rita Cabrita;Martin Lauss;Adriana Sanna;Marco Donia

  • Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

    Unknown

  • Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

    Unknown

  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Paolo A. Ascierto;Michele Del Vecchio;Caroline Robert;Andrzej Mackiewicz

  • Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

    Martin Lauss;Marco Donia;Katja Harbst;Rikke Andersen

  • Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

    Celeste Lebbé;Nicolas Meyer;Laurent Mortier;Ivan Marquez-Rodas

  • Collagen density regulates the activity of tumor-infiltrating T cells

    Dorota E. Kuczek;Anne Mette Hvid Larsen;Anne Mette Hvid Larsen;Marie-Louise Thorseth;Marco Carretta

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Alexander M M Eggermont;Christian U Blank;Mario Mandalà;Georgina V Long

  • Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

    Amalie Kai Bentzen;Andrea Marion Marquard;Rikke Lyngaa;Sunil Kumar Saini

  • Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

    Paolo A. Ascierto;Georgina V. Long;Georgina V. Long;Caroline Robert;Benjamin Brady

  • Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Paolo Antonio Ascierto;Pier Francesco Ferrucci;Rosalie Fisher;Michele Del Vecchio

  • Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

    Rikke Andersen;Marco Donia;Eva Ellebaek;Troels Holz Borch

  • Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

    Marie Klinge Brimnes;Annette Juul Vangsted;Lene Meldgaard Knudsen;Peter Gimsing

  • Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

    Lotte Engell-Noerregaard;Troels Holz Hansen;Mads Hald Andersen;Per thor Straten

  • Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Michael D. Crowther;Garry Dolton;Mateusz Legut;Marine E. Caillaud

  • The universal character of the tumor-associated antigen survivin.

    Mads Hald Andersen;Inge Marie Svane;Jürgen C. Becker;Per thor Straten

  • Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

    U Dafni;U Dafni;O Michielin;S Martin Lluesma;S Martin Lluesma;Z Tsourti

  • Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

    Y.J.L. Jansen;E.A. Rozeman;R. Mason;S.M. Goldinger

  • Principles of adoptive T cell therapy in cancer.

    Özcan Met;Özcan Met;Kasper Mølgaard Jensen;Christopher Aled Chamberlain;Marco Donia

  • Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

    Eva Ellebaek;Trine Zeeberg Iversen;Niels Junker;Marco Donia;Marco Donia

  • Predictors of responses to immune checkpoint blockade in advanced melanoma.

    N Jacquelot;N Jacquelot;M P Roberti;D P Enot;S Rusakiewicz

Frequent Co-Authors

Mads Hald Andersen
Mads Hald Andersen Copenhagen University Hospital
Marco Donia
Marco Donia Copenhagen University Hospital
Per thor Straten
Per thor Straten University of Copenhagen
Sine Reker Hadrup
Sine Reker Hadrup Technical University of Denmark
Morten Hartvig Hansen
Morten Hartvig Hansen University of Southern Denmark
Jürgen C. Becker
Jürgen C. Becker University of Duisburg-Essen
Göran Jönsson
Göran Jönsson Lund University
Georgina V. Long
Georgina V. Long University of Sydney
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology in the USA opens diverse career avenues, especially when combined with advanced nursing degrees. Many professionals look for programs that balance quality and affordability, such as the cheapest psych np programs online, which offer accessible pathways into specialized healthcare roles.

For those interested in further specialization, understanding the highest paid dnp specialties helps guide career decisions, ensuring a strategic focus on both impact and financial reward. Transitioning between nursing roles is also common, with resources available to support shifts such as the fnp to acute care certification, which prepares nurses to handle complex cases linked to immunological conditions.

Accelerated pathways like the accelerated rn to np programs enable students with foundational nursing backgrounds to quickly advance their qualifications, making it easier to enter immunology-related specialties backed by nurse practitioner credentials. These combined options highlight the flexibility and breadth of study and career growth in immunology and healthcare.

Best Scientists Citing Inge Marie Svane

Trending Scientists

Recently Published Articles